Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
NASDAQ:RLYB

Rallybio Q1 2026 Earnings Results & Report

Rallybio logo
$16.28 -0.49 (-2.92%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$16.33 +0.05 (+0.31%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rallybio missed analyst earnings expectations and met on revenue in its Q1 2026 results, released May 13, 2026. The company reported EPS of -$1.46 versus the -$1.20 consensus estimate, while revenue of $0.21 million matched the $0.21 million estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Rallybio EPS Results

Actual EPS
-$1.46
Consensus EPS
-$1.20
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Rallybio Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.21 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Upcoming Earnings

Rallybio's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Rallybio Q1 2026 Earnings FAQ

Rallybio (NASDAQ:RLYB) reported earnings of -$1.46 per share for Q1 2026, missing the consensus estimate of -$1.20. The report was announced on Wednesday, May 13, 2026.

Rallybio reported revenue of $0.21 million for Q1 2026, against a consensus estimate of $0.21 million.

Rallybio's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rallybio on the company's earnings history page.

Rallybio Earnings Headlines

Head to Head Analysis: Alector (NASDAQ:ALEC) & Rallybio (NASDAQ:RLYB)
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109788
Rallybio CFO Transition Amid Pending Avenzo Therapeutics Merger
September 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rallybio-cfo-transition-amid-pending-avenzo-therapeutics-merger?utm_source=marketbeat.com&utm_medium=referral
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
 |  Weiss Ratings (Ad)
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
June 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260602266487/en/rallybio-investor-alert-kahn-swick-foti-llc-investigates-merger-of-rallybio-corporation---rlyb/
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
June 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rlyb-stock-hits-2-highs-162629816.html
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
June 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260601190294/en/RLYB-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-Rallybio-Corporation-is-Obtaining-a-Fair-Price-for-its-Shareholders/
See More Rallybio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rallybio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rallybio and other key companies, straight to your email.

About Rallybio

Rallybio (NASDAQ:RLYB) is a clinical-stage biotechnology company focused on developing medicines for rare diseases and conditions with significant unmet medical needs. The company’s research and development efforts are directed toward therapies that address serious disorders in areas such as maternal-fetal health, hematology and immunology.

Rallybio’s lead program, RLYB212, is designed to prevent hemolytic disease of the fetus and newborn caused by maternal alloimmunization against the Kell antigen. The company has also developed investigational therapies that target the complement system, an immune pathway involved in a range of rare and severe diseases.

Founded in 2018, Rallybio is headquartered in New Haven, Connecticut. Its programs are being developed through clinical research intended to support potential future treatments in the United States and other markets, subject to regulatory approval. The company’s management and development teams include biotechnology and pharmaceutical industry professionals with experience in drug discovery, clinical development and commercialization.

View Rallybio Profile
Earnings Tools